BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 27, 2007
View Archived Issues
Some Blunt Talk About Money Highlights Kickoff of EuroBIO
Read More
Keryx, Japan Tobacco Deal: Possible $100M For Zerenex
Read More
Partnering Tables Turn As Big Pharma Pitches Biotech
Read More
Alemtuzumab In Phase III Testing Against Rebif In MS
Read More
GlobeImmune Is Advancing Tarmogen With $41M Series C
Read More
Amgen Cutbacks Hit Home As ECCO Data Tumble Forth
Read More
CollaGenex Drops Rosacea Drug After Phase II Failure
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Emergent Snags $448M Deal for Anthrax Vaccine
Emergent BioSolutions Inc. said Wednesday that it signed a three-year contract with the federal government worth up to $448 million to supply anthrax vaccine for the nation's biodefense stockpile. (BioWorld Today)
Read More
NPS, Nycomed Enter Potential $185M Deal Covering Gattex
Read More